Search

Your search keyword '"Vanwolleghem, Thomas"' showing total 461 results

Search Constraints

Start Over You searched for: Author "Vanwolleghem, Thomas" Remove constraint Author: "Vanwolleghem, Thomas"
461 results on '"Vanwolleghem, Thomas"'

Search Results

2. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD

4. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

5. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy

6. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis

8. Predictors of hepatic flares after nucleos(t)ide analogue cessation – Results of a global cohort study (RETRACT-B study)

9. Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

10. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

11. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

12. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B

13. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis

14. Viral clade is associated with severity of symptomatic genotype 3 hepatitis E virus infections in Belgium, 2010–2018

15. WED-372 Downregulation of soluble FASLG as a potential mechanism of enhanced immune-related clearance of infected hepatocytes induced by JNJ-73763989 in HBeAg-negative virologically suppressed chronic hepatitis B patients

17. OS-096-YI Spleen stiffness measurement by transient elastography at 100 Hz refines the non-invasive diagnosis of clinically significant portal hypertension in compensated advanced chronic liver diseasefinal results of a european multicenter study

18. FRI-043 A multi-center randomized controlled study of primary prevention of esophageal variceal bleeding in cirrhotic patients treated with HVPG-guided therapy or standard heart rate-guided therapy: an interim analysis of the PORTHOS trial

19. FRI-406 Real world outcomes of hepatitis delta patients with mild or moderate fibrosis

21. SAT-051 The clinical relevance of prior bariatric surgery in alcohol-related liver disease in a nationwide belgian liver transplant population

23. SAT-337 Serum levels of IgA inform on the transcriptomic architecture of the liver and predict hepatocellular carcinoma in chronic viral hepatitis patients

25. WED-379 Intrahepatic changes in immunologic and virologic markers during siRNA JNJ-73763989 (JNJ-3989) based treatment of chronic hepatitis B (CHB) patients: imaging mass cytometry (IMC) analyses from the INSIGHT study

26. TOP-401-YI Improvement of liver stiffness during nucleo (s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk

27. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease

29. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial

30. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

31. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)

32. Long‐term outcome of hepatitis delta in different regions world‐wide: Results of the Hepatitis Delta International Network.

33. Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).

35. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy

36. Patient profiled data for treatment decision-making:valuable as an add-on to hepatitis C clinical guidelines?

39. Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease

40. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

42. Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis

44. Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial)

46. Predictors of severe flares after nucleos (t)ide analogue cessation-results of a global cohort study (RETRACT-B study)

47. Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study

48. Natural history of patients with NAFLD-associated compensated advanced chronic liver disease stratified according to severity of portal hypertension

49. Utility of partial cure as an end point after nucleos (t)ide analogue withdrawal among chronic hepatitis B patients (RETRACT-B study)

50. Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm

Catalog

Books, media, physical & digital resources